 | • レポートコード：QFJ1-4345 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、特発性肺線維症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品クラス、酸素療法、肺移植、その他）、用途別市場規模（病院、診療所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・特発性肺線維症治療の市場動向 ・企業の競争状況、市場シェア ・特発性肺線維症治療の種類別市場規模と予測2016-2027（医薬品クラス、酸素療法、肺移植、その他） ・特発性肺線維症治療の用途別市場規模と予測2016-2027（病院、診療所） ・特発性肺線維症治療の北米市場規模2016-2027（アメリカ、カナダ） ・特発性肺線維症治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・特発性肺線維症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・特発性肺線維症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・特発性肺線維症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Biogen、Boehringer Ingelheim GMBH、Bristol-Myers Squibb Company、Cipla、Hoffmann-La Roche AG、Fibrogen, Inc.、Galapagos NV、Medicinova, Inc.、Merck & Co., Inc.、Novartis AG、Prometic Life Sciences Inc.） ・結論 |
Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff.
Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Treatment Market
The global Idiopathic Pulmonary Fibrosis Treatment market size is projected to reach US$ 3180 million by 2027, from US$ 1895.9 million in 2020, at a CAGR of 7.2% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Idiopathic Pulmonary Fibrosis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Idiopathic Pulmonary Fibrosis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Idiopathic Pulmonary Fibrosis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Idiopathic Pulmonary Fibrosis Treatment market.
Global Idiopathic Pulmonary Fibrosis Treatment Scope and Market Size
Idiopathic Pulmonary Fibrosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Pulmonary Fibrosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Drug Class
Oxygen Therapy
Lung Transplant
Others
Segment by Application
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Biogen
Boehringer Ingelheim GMBH
Bristol-Myers Squibb Company
Cipla
Hoffmann-La Roche AG
Fibrogen, Inc.
Galapagos NV
Medicinova, Inc.
Merck & Co., Inc.
Novartis AG
Prometic Life Sciences Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Class
1.2.3 Oxygen Therapy
1.2.4 Lung Transplant
1.2.5 Others
1.3 Market by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Perspective (2016-2027)
2.2 Idiopathic Pulmonary Fibrosis Treatment Growth Trends by Regions
2.2.1 Idiopathic Pulmonary Fibrosis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Idiopathic Pulmonary Fibrosis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Idiopathic Pulmonary Fibrosis Treatment Industry Dynamic
2.3.1 Idiopathic Pulmonary Fibrosis Treatment Market Trends
2.3.2 Idiopathic Pulmonary Fibrosis Treatment Market Drivers
2.3.3 Idiopathic Pulmonary Fibrosis Treatment Market Challenges
2.3.4 Idiopathic Pulmonary Fibrosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Pulmonary Fibrosis Treatment Players by Revenue
3.1.1 Global Top Idiopathic Pulmonary Fibrosis Treatment Players by Revenue (2016-2021)
3.1.2 Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Pulmonary Fibrosis Treatment Revenue
3.4 Global Idiopathic Pulmonary Fibrosis Treatment Market Concentration Ratio
3.4.1 Global Idiopathic Pulmonary Fibrosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Treatment Revenue in 2020
3.5 Idiopathic Pulmonary Fibrosis Treatment Key Players Head office and Area Served
3.6 Key Players Idiopathic Pulmonary Fibrosis Treatment Product Solution and Service
3.7 Date of Enter into Idiopathic Pulmonary Fibrosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Pulmonary Fibrosis Treatment Breakdown Data by Type
4.1 Global Idiopathic Pulmonary Fibrosis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Type (2022-2027)
5 Idiopathic Pulmonary Fibrosis Treatment Breakdown Data by Application
5.1 Global Idiopathic Pulmonary Fibrosis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
6.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
6.2.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
6.2.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
6.2.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
6.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
6.3.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
6.3.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
6.3.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
6.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
6.4.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
6.4.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
7.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
7.2.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
7.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
7.3.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
7.4 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
7.4.1 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
8.2.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
8.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region
8.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
9.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
9.2.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
9.3 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
9.3.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
9.4 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
9.4.1 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type
10.2.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application
10.3.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country
10.4.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Idiopathic Pulmonary Fibrosis Treatment Introduction
11.1.4 Biogen Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Boehringer Ingelheim GMBH
11.2.1 Boehringer Ingelheim GMBH Company Details
11.2.2 Boehringer Ingelheim GMBH Business Overview
11.2.3 Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Introduction
11.2.4 Boehringer Ingelheim GMBH Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.2.5 Boehringer Ingelheim GMBH Recent Development
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Details
11.3.2 Bristol-Myers Squibb Company Business Overview
11.3.3 Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Introduction
11.3.4 Bristol-Myers Squibb Company Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.3.5 Bristol-Myers Squibb Company Recent Development
11.4 Cipla
11.4.1 Cipla Company Details
11.4.2 Cipla Business Overview
11.4.3 Cipla Idiopathic Pulmonary Fibrosis Treatment Introduction
11.4.4 Cipla Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.4.5 Cipla Recent Development
11.5 Hoffmann-La Roche AG
11.5.1 Hoffmann-La Roche AG Company Details
11.5.2 Hoffmann-La Roche AG Business Overview
11.5.3 Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Introduction
11.5.4 Hoffmann-La Roche AG Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.5.5 Hoffmann-La Roche AG Recent Development
11.6 Fibrogen, Inc.
11.6.1 Fibrogen, Inc. Company Details
11.6.2 Fibrogen, Inc. Business Overview
11.6.3 Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.6.4 Fibrogen, Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.6.5 Fibrogen, Inc. Recent Development
11.7 Galapagos NV
11.7.1 Galapagos NV Company Details
11.7.2 Galapagos NV Business Overview
11.7.3 Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Introduction
11.7.4 Galapagos NV Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.7.5 Galapagos NV Recent Development
11.8 Medicinova, Inc.
11.8.1 Medicinova, Inc. Company Details
11.8.2 Medicinova, Inc. Business Overview
11.8.3 Medicinova, Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.8.4 Medicinova, Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.8.5 Medicinova, Inc. Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.9.5 Merck & Co., Inc. Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Details
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Idiopathic Pulmonary Fibrosis Treatment Introduction
11.10.4 Novartis AG Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.10.5 Novartis AG Recent Development
11.11 Prometic Life Sciences Inc.
11.11.1 Prometic Life Sciences Inc. Company Details
11.11.2 Prometic Life Sciences Inc. Business Overview
11.11.3 Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Introduction
11.11.4 Prometic Life Sciences Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
11.11.5 Prometic Life Sciences Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Class
Table 3. Key Players of Oxygen Therapy
Table 4. Key Players of Lung Transplant
Table 5. Key Players of Others
Table 6. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Regions (2016-2021)
Table 10. Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Regions (2022-2027)
Table 12. Idiopathic Pulmonary Fibrosis Treatment Market Trends
Table 13. Idiopathic Pulmonary Fibrosis Treatment Market Drivers
Table 14. Idiopathic Pulmonary Fibrosis Treatment Market Challenges
Table 15. Idiopathic Pulmonary Fibrosis Treatment Market Restraints
Table 16. Global Idiopathic Pulmonary Fibrosis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Players (2016-2021)
Table 18. Global Top Idiopathic Pulmonary Fibrosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis Treatment as of 2020)
Table 19. Ranking of Global Top Idiopathic Pulmonary Fibrosis Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Idiopathic Pulmonary Fibrosis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Idiopathic Pulmonary Fibrosis Treatment Product Solution and Service
Table 23. Date of Enter into Idiopathic Pulmonary Fibrosis Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Idiopathic Pulmonary Fibrosis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Idiopathic Pulmonary Fibrosis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Biogen Company Details
Table 64. Biogen Business Overview
Table 65. Biogen Idiopathic Pulmonary Fibrosis Treatment Product
Table 66. Biogen Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 67. Biogen Recent Development
Table 68. Boehringer Ingelheim GMBH Company Details
Table 69. Boehringer Ingelheim GMBH Business Overview
Table 70. Boehringer Ingelheim GMBH Idiopathic Pulmonary Fibrosis Treatment Product
Table 71. Boehringer Ingelheim GMBH Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 72. Boehringer Ingelheim GMBH Recent Development
Table 73. Bristol-Myers Squibb Company Company Details
Table 74. Bristol-Myers Squibb Company Business Overview
Table 75. Bristol-Myers Squibb Company Idiopathic Pulmonary Fibrosis Treatment Product
Table 76. Bristol-Myers Squibb Company Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 77. Bristol-Myers Squibb Company Recent Development
Table 78. Cipla Company Details
Table 79. Cipla Business Overview
Table 80. Cipla Idiopathic Pulmonary Fibrosis Treatment Product
Table 81. Cipla Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 82. Cipla Recent Development
Table 83. Hoffmann-La Roche AG Company Details
Table 84. Hoffmann-La Roche AG Business Overview
Table 85. Hoffmann-La Roche AG Idiopathic Pulmonary Fibrosis Treatment Product
Table 86. Hoffmann-La Roche AG Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 87. Hoffmann-La Roche AG Recent Development
Table 88. Fibrogen, Inc. Company Details
Table 89. Fibrogen, Inc. Business Overview
Table 90. Fibrogen, Inc. Idiopathic Pulmonary Fibrosis Treatment Product
Table 91. Fibrogen, Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 92. Fibrogen, Inc. Recent Development
Table 93. Galapagos NV Company Details
Table 94. Galapagos NV Business Overview
Table 95. Galapagos NV Idiopathic Pulmonary Fibrosis Treatment Product
Table 96. Galapagos NV Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 97. Galapagos NV Recent Development
Table 98. Medicinova, Inc. Company Details
Table 99. Medicinova, Inc. Business Overview
Table 100. Medicinova, Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 101. Medicinova, Inc. Recent Development
Table 102. Merck & Co., Inc. Company Details
Table 103. Merck & Co., Inc. Business Overview
Table 104. Merck & Co., Inc. Idiopathic Pulmonary Fibrosis Treatment Product
Table 105. Merck & Co., Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 106. Merck & Co., Inc. Recent Development
Table 107. Novartis AG Company Details
Table 108. Novartis AG Business Overview
Table 109. Novartis AG Idiopathic Pulmonary Fibrosis Treatment Product
Table 110. Novartis AG Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 111. Novartis AG Recent Development
Table 112. Prometic Life Sciences Inc. Company Details
Table 113. Prometic Life Sciences Inc. Business Overview
Table 114. Prometic Life Sciences Inc. Idiopathic Pulmonary Fibrosis Treatment Product
Table 115. Prometic Life Sciences Inc. Revenue in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021) & (US$ Million)
Table 116. Prometic Life Sciences Inc. Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drug Class Features
Figure 3. Oxygen Therapy Features
Figure 4. Lung Transplant Features
Figure 5. Others Features
Figure 6. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Idiopathic Pulmonary Fibrosis Treatment Report Years Considered
Figure 10. Global Idiopathic Pulmonary Fibrosis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Idiopathic Pulmonary Fibrosis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Regions (2022-2027)
Figure 14. Global Idiopathic Pulmonary Fibrosis Treatment Market Share by Players in 2020
Figure 15. Global Top Idiopathic Pulmonary Fibrosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Treatment Revenue in 2020
Figure 17. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Idiopathic Pulmonary Fibrosis Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Idiopathic Pulmonary Fibrosis Treatment Market Share by Type (2016-2027)
Figure 21. North America Idiopathic Pulmonary Fibrosis Treatment Market Share by Application (2016-2027)
Figure 22. North America Idiopathic Pulmonary Fibrosis Treatment Market Share by Country (2016-2027)
Figure 23. United States Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Idiopathic Pulmonary Fibrosis Treatment Market Share by Type (2016-2027)
Figure 27. Europe Idiopathic Pulmonary Fibrosis Treatment Market Share by Application (2016-2027)
Figure 28. Europe Idiopathic Pulmonary Fibrosis Treatment Market Share by Country (2016-2027)
Figure 29. Germany Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Idiopathic Pulmonary Fibrosis Treatment Market Share by Region (2016-2027)
Figure 39. China Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Idiopathic Pulmonary Fibrosis Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Idiopathic Pulmonary Fibrosis Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Idiopathic Pulmonary Fibrosis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Biogen Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 59. Boehringer Ingelheim GMBH Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 61. Cipla Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 62. Hoffmann-La Roche AG Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 63. Fibrogen, Inc. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 64. Galapagos NV Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 65. Medicinova, Inc. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 66. Merck & Co., Inc. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 67. Novartis AG Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 68. Prometic Life Sciences Inc. Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Treatment Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
特発性肺線維症治療のグローバル市場：規模・現状・予測2019-2025 Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff. In 2018, the global Idiopathic Pulmonary Fibrosis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of …- 特発性肺線維症治療のグローバル市場：規模・現状・予測2019-2025 Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff. In 2018, the global Idiopathic Pulmonary Fibrosis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of …
- 特発性肺線維症治療のグローバル市場：規模・現状・予測2019-2025 Idiopathic Pulmonary Fibrosis Treatment is treatment work on a lung disease which causes the tissue in your lungs to become stiff. In 2018, the global Idiopathic Pulmonary Fibrosis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of …
- 特発性肺線維症薬のグローバル市場調査 2019年 The global Idiopathic Pulmonary Fibrosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Idiopathic Pulmonary Fibrosis Drug volume and value at global level, regional level and company level. F…
- 世界の肺・気道疾患治療市場規模・現状・予測（2021年-2027年） Lung (Pulmonary) Airway Disease include bronchiectasis, asthma and COPD.Disease narrow down or block the airways. Such breathing problems caused due to Lung (Pulmonary) Airway Disease may inhibit the body receiving sufficient oxygen. Market Analysis and Insights: Global Lung Pulmonary Airway Disease…